krystal biotech inc - KRYS
KRYS
Close Chg Chg %
248.91 12.50 5.02%
Closed Market
261.41
+12.50 (5.02%)
Volume: 349.87K
Last Updated:
Jan 9, 2026, 4:00 PM EDT
Company Overview: krystal biotech inc - KRYS
KRYS Key Data
| Open $254.51 | Day Range 252.92 - 267.48 |
| 52 Week Range 123.03 - 267.48 | Market Cap $7.14B |
| Shares Outstanding 29.00M | Public Float 24.93M |
| Beta 0.46 | Rev. Per Employee N/A |
| P/E Ratio 37.41 | EPS $6.89 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 280.08K |
KRYS Performance
| 1 Week | 5.87% | ||
| 1 Month | 6.85% | ||
| 3 Months | 44.05% | ||
| 1 Year | 70.95% | ||
| 5 Years | 294.11% |
KRYS Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
12
Full Ratings ➔
About krystal biotech inc - KRYS
Krystal Biotech, Inc. operates as a biotechnology company, which engages in developing and commercializing pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
KRYS At a Glance
Krystal Biotech, Inc.
2100 Wharton Street
Pittsburgh, Pennsylvania 15203
| Phone | 1-412-586-5830 | Revenue | 290.52M | |
| Industry | Biotechnology | Net Income | 89.16M | |
| Sector | Health Technology | 2024 Sales Growth | 473.019% | |
| Fiscal Year-end | 12 / 2025 | Employees | 275 | |
| View SEC Filings |
KRYS Valuation
| P/E Current | 37.407 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 52.255 |
| Price to Sales Ratio | 16.037 |
| Price to Book Ratio | 4.766 |
| Price to Cash Flow Ratio | 37.75 |
| Enterprise Value to EBITDA | 37.009 |
| Enterprise Value to Sales | 14.006 |
| Total Debt to Enterprise Value | 0.002 |
KRYS Efficiency
| Revenue/Employee | 1,056,418.182 |
| Income Per Employee | 324,214.545 |
| Receivables Turnover | 2.774 |
| Total Asset Turnover | 0.31 |
KRYS Liquidity
| Current Ratio | 7.275 |
| Quick Ratio | 7.015 |
| Cash Ratio | 5.858 |
KRYS Profitability
| Gross Margin | 90.772 |
| Operating Margin | 35.521 |
| Pretax Margin | 32.823 |
| Net Margin | 30.69 |
| Return on Assets | 9.514 |
| Return on Equity | 10.337 |
| Return on Total Capital | 9.349 |
| Return on Invested Capital | 10.262 |
KRYS Capital Structure
| Total Debt to Total Equity | 0.767 |
| Total Debt to Total Capital | 0.761 |
| Total Debt to Total Assets | 0.688 |
| Long-Term Debt to Equity | 0.639 |
| Long-Term Debt to Total Capital | 0.634 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Krystal Biotech Inc - KRYS
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | 50.70M | 290.51M | - |
Sales Growth
| - | - | - | +473.02% | - |
Cost of Goods Sold (COGS) incl D&A
| 2.77M | 4.05M | 8.10M | 26.81M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 2.77M | 4.05M | 5.01M | 6.75M | |
Depreciation
| 1.80M | 2.60M | 5.01M | 6.75M | |
Amortization of Intangibles
| - | - | 969.00K | 1.46M | - |
COGS Growth
| +49.59% | +46.44% | +99.78% | +230.92% | |
Gross Income
| (2.77M) | (4.05M) | 42.60M | 263.71M | |
Gross Income Growth
| -49.59% | -46.44% | +1,150.51% | +519.06% | |
Gross Profit Margin
| - | - | +84.02% | +90.77% | - |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 65.51M | 116.14M | 139.82M | 160.51M | |
Research & Development
| 26.08M | 39.86M | 46.43M | 53.57M | |
Other SG&A
| 39.42M | 76.28M | 93.39M | 106.94M | |
SGA Growth
| +110.31% | +77.30% | +20.39% | +14.79% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 25.00M | 12.50M | 37.50M | |
EBIT after Unusual Expense
| (68.28M) | (145.20M) | (109.73M) | 65.69M | |
Non Operating Income/Expense
| (1.29M) | 5.22M | 122.62M | 29.66M | |
Non-Operating Interest Income
| 197.00K | 5.22M | 22.62M | 29.66M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (69.57M) | (139.97M) | 12.90M | 95.36M | |
Pretax Income Growth
| -116.28% | -101.20% | +109.21% | +639.37% | |
Pretax Margin
| - | - | +25.44% | +32.82% | - |
Income Tax
| - | - | 1.97M | 6.20M | - |
Income Tax - Current - Domestic
| - | - | 1.83M | 6.04M | - |
Income Tax - Current - Foreign
| - | - | 138.00K | 153.00K | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (69.57M) | (139.97M) | 10.93M | 89.16M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (69.57M) | (139.97M) | 10.93M | 89.16M | |
Net Income Growth
| -116.28% | -101.20% | +107.81% | +715.58% | |
Net Margin Growth
| - | - | +21.56% | +30.69% | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (69.57M) | (139.97M) | 10.93M | 89.16M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (69.57M) | (139.97M) | 10.93M | 89.16M | |
EPS (Basic)
| -3.1342 | -5.491 | 0.4026 | 3.1183 | |
EPS (Basic) Growth
| -83.05% | -75.20% | +107.33% | +674.54% | |
Basic Shares Outstanding
| 22.20M | 25.49M | 27.15M | 28.59M | |
EPS (Diluted)
| -3.1342 | -5.491 | 0.3939 | 2.998 | |
EPS (Diluted) Growth
| -83.05% | -75.20% | +107.17% | +661.11% | |
Diluted Shares Outstanding
| 22.20M | 25.49M | 27.75M | 29.74M | |
EBITDA
| (65.51M) | (116.14M) | (92.22M) | 109.94M | |
EBITDA Growth
| -110.31% | -77.30% | +20.60% | +219.22% | |
EBITDA Margin
| - | - | -181.90% | +37.84% | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 272.30 | |
| Number of Ratings | 12 | Current Quarters Estimate | 1.54 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 7.72 | |
| Last Quarter’s Earnings | 1.54 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 6.655 | Next Fiscal Year Estimate | 10.185 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | 5 | 12 | 9 |
| Mean Estimate | 1.54 | 1.95 | 7.72 | 10.19 |
| High Estimates | 2.13 | 2.46 | 9.79 | 20.57 |
| Low Estimate | 1.03 | 1.49 | 4.51 | 3.79 |
| Coefficient of Variance | 26.62 | 18.86 | 19.97 | 49.89 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 12 | 11 | 11 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Krystal Biotech Inc - KRYS
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Krystal Biotech Inc - KRYS
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 14, 2025 | Krish S. Krishnan President and CEO; Director | 1,463,711 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $179.55 per share | 262,809,310.05 |
| Mar 14, 2025 | Krish S. Krishnan President and CEO; Director | 1,487,072 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $175.97 per share | 261,680,059.84 |
| Mar 14, 2025 | Krish S. Krishnan President and CEO; Director | 1,482,493 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $176.88 per share | 262,223,361.84 |
| Mar 14, 2025 | Krish S. Krishnan President and CEO; Director | 1,533,056 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $179.57 per share | 275,290,865.92 |
| Mar 14, 2025 | Krish S. Krishnan President and CEO; Director | 1,534,312 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $178.77 per share | 274,288,956.24 |
| Mar 14, 2025 | Krish S. Krishnan President and CEO; Director | 1,541,081 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $177.62 per share | 273,726,807.22 |
| Mar 14, 2025 | Krish S. Krishnan President and CEO; Director | 1,552,012 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $176.8 per share | 274,395,721.60 |
| Mar 14, 2025 | Krish S. Krishnan President and CEO; Director | 1,556,956 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $175.83 per share | 273,759,573.48 |
| Mar 14, 2025 | Krish S. Krishnan President and CEO; Director | 1,471,556 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $177.66 per share | 261,436,638.96 |
| Mar 14, 2025 | Krish S. Krishnan President and CEO; Director | 1,465,042 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $178.76 per share | 261,890,907.92 |
| Mar 14, 2025 | Suma M. Krishnan President, R&D; Director | 1,487,072 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $175.97 per share | 261,680,059.84 |
| Mar 14, 2025 | Suma M. Krishnan President, R&D; Director | 1,533,056 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $179.57 per share | 275,290,865.92 |
| Mar 14, 2025 | Suma M. Krishnan President, R&D; Director | 1,534,312 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $178.77 per share | 274,288,956.24 |
| Mar 14, 2025 | Suma M. Krishnan President, R&D; Director | 1,541,081 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $177.62 per share | 273,726,807.22 |
| Mar 14, 2025 | Suma M. Krishnan President, R&D; Director | 1,552,012 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $176.8 per share | 274,395,721.60 |
| Mar 14, 2025 | Suma M. Krishnan President, R&D; Director | 1,556,956 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $175.83 per share | 273,759,573.48 |
| Mar 14, 2025 | Suma M. Krishnan President, R&D; Director | 1,463,711 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $179.55 per share | 262,809,310.05 |
| Mar 14, 2025 | Suma M. Krishnan President, R&D; Director | 1,465,042 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $178.76 per share | 261,890,907.92 |
| Mar 14, 2025 | Suma M. Krishnan President, R&D; Director | 1,471,556 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $177.66 per share | 261,436,638.96 |
| Mar 14, 2025 | Suma M. Krishnan President, R&D; Director | 1,482,493 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $176.88 per share | 262,223,361.84 |